Valuation: Repligen Corporation

Market Cap 10.22B 8.76B 8.19B 7.5B 14.08B 978B 14.26B 96.8B 37.75B 491B 38.38B 37.55B 1,625B P/E 2026 *
240x
P/E 2027 * 105x
Enterprise Value 9.99B 8.56B 8.01B 7.33B 13.75B 956B 13.93B 94.59B 36.89B 480B 37.51B 36.69B 1,588B EV / Sales 2026 *
12.1x
EV / Sales 2027 * 10.1x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+2.17%
1 week+6.30%
Current month+23.33%
1 month+24.34%
3 months+58.59%
6 months+32.37%
Current year+9.77%
1 week 141.75
Extreme 141.75
152.75
1 month 113.75
Extreme 113.75
152.75
Current year 86.32
Extreme 86.32
152.75
1 year 86.32
Extreme 86.32
152.75
3 years 86.32
Extreme 86.32
192
5 years 86.32
Extreme 86.32
278.7
10 years 23.77
Extreme 23.769
278.7
Manager TitleAgeSince
Chief Executive Officer 56 01/09/2024
Director of Finance/CFO 52 25/09/2023
Chief Tech/Sci/R&D Officer - 01/08/2025
Director TitleAgeSince
Chairman 74 14/12/2011
Director/Board Member 60 12/06/2014
Director/Board Member 67 01/10/2015
Change 5-day change 1-year change 3-year change Capi.($)
+2.17%+6.30% - - 10.22B
+2.19%+4.84%-12.03%+10.93% 202B
+1.14%+2.28%+0.69%+11.50% 119B
+1.06%+1.34%+8.69%+78.71% 60.69B
-1.37%-6.57%+30.31%+55.01% 52.38B
+2.33%+4.69%-3.84%-30.36% 52.3B
+2.35%+2.89%+12.25%-13.68% 34.85B
+5.16%-4.14% - - 30.06B
-0.20%+1.05%+42.46%-10.20% 24.85B
-0.29%-3.87%-6.19%+25.59% 23.84B
Average +1.45%+0.28%+9.04%+15.94% 66.7B
Weighted average by Cap. +1.54%+1.90%+1.58%+16.71%

Financials

2026 *2027 *
Net sales 827M 708M 663M 607M 1.14B 79.13B 1.15B 7.83B 3.05B 39.75B 3.11B 3.04B 131B 969M 830M 777M 711M 1.33B 92.74B 1.35B 9.18B 3.58B 46.59B 3.64B 3.56B 154B
Net income 41.92M 35.91M 33.6M 30.76M 57.72M 4.01B 58.49M 397M 155M 2.01B 157M 154M 6.66B 98.84M 84.67M 79.22M 72.52M 136M 9.46B 138M 936M 365M 4.75B 371M 363M 15.71B
Net Debt -234M -200M -187M -171M -322M -22.36B -326M -2.21B -863M -11.23B -877M -858M -37.15B -407M -349M -326M -299M -561M -38.97B -568M -3.86B -1.5B -19.58B -1.53B -1.5B -64.75B
Logo Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.
Employees
2,000
Date Price Change
21/08/26 €152.75 +2.17%
20/08/26 €149.50 +5.47%
19/08/26 €141.75 -1.77%
18/08/26 €144.30 +1.48%
17/08/26 €142.20 -1.04%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
181.13USD
Average target price
185.70USD
Spread / Average Target
+2.52%

Quarterly revenue - Rate of surprise